LATEST NEWS
MindImmune Caps Off a $30M Series A Round
Dec 1, 2025
MindImmune has just capped a $30M Series A round. Funds will support the company through an IND and then into the clinic.
News
MindImmune Therapeutics Announces $12.4 million Series A Financing
.webp)
MindImmune Appoints Thomas Prod’homme, Ph.D., as Vice President, Preclinical Development
.webp)
MindImmune Awarded Grant to Accelerate IND-Enabling Studies through Rhode Island Life Science Hub
Wheeler Bio and MindImmune Therapeutics Sign CDMO Partnership Agreement to Support MindImmune's Lead Alzheimer's Prevention Program, MITI-101
Fab Five: First Ocean State Labs life sciences tenants announced
Governor McKee, RI Life Science Hub Announce Five Foundational Companies for Ocean State Labs
A scientific breakthrough on treating Alzheimer’s disease (Part 1)
A new paradigm for treating autoimmune diseases of the brain (Part 2)
Developing Antibodies To Block Neuroinflammation With MindImmune's Stevin Zorn, Ph.D.
MindImmune Extends Series A to $30M to Advance Inflammation-Focused Alzheimer’s Therapy into the Clinic and Appoints Isaac Stoner as CEO
Good news: Alzheimer’s disease solution poised to enter clinic in 2026 (PART 1)
The hospitals’ survival polka (PART 2)
MindImmune Therapeutics $30M funding round, 6th tenant set stage for Ocean State Labs opening
